See our exclusive index of companies on the move:
Explore Stocks- Top Stocks
- Top Australian Gold Stocks
- Top ASX Copper Stocks
- Top ASX Nickel Stocks
- Top ASX Rare Earth Stocks
- Top Battery Metals Stocks on the ASX
- Top Australian Lithium Stocks
- Top Graphite Miners on the ASX
- 10 ASX Cannabis Stocks
- Top ASX Tech Stocks
- Top AI Stocks on the ASX
- On Site
- About Australian Cannabis Investing
- About Australian Resource Investing
- About Australian Tech Investing
- About Australia Investing
- Of Interest
- ASEAN-Australia-New Zealand Trade Agreement
- Association of Southeast Asian Nations (ASEAN)
- Australian FAQ on ASEAN
- Australia Government on Foreign Investments
Medlab Clinical released its Appendix 4C results for its most recent quarter of operations.
Medlab Clinical (ASX:MDC) released its Appendix 4C results for its most recent quarter of operations.
As quoted in the press release:
The key highlights for the period have been:
- Recruitment in Medlab’s Phase 2 trial at Royal North Shore Hospital is completed and results expected by Christmas.
- Collections of AU$2.401m, an increase of approx. 96 percent over the corresponding period last year.
- R&D Tax Incentive FY 2019 of AU$2.1m was received in October.
- Agreement executed to expand nutraceuticals to USA
- First export order of Medlab’s newest cannabinoid (NanoCBD) of 1,500 units to Hong Kong received and deposit paid.
RESEARCH
Medlab’s research programme, specifically in pain management and depression continues to progress well. These two specific areas represent extremely large patient groups with unmet needs and significant potential global revenue models.
Top News
FEATURED STOCKS
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.